How much funding has Arsia Therapeutics raised?

Arsia Therapeutics has raised $1.1M in total funding, most recently a Series A round.

Who are Arsia Therapeutics's investors?

Arsia Therapeutics's investors include Polaris Partners, Eagle Pharmaceuticals.

When was Arsia Therapeutics founded?

Arsia Therapeutics was founded in 2013.

Where is Arsia Therapeutics headquartered?

Arsia Therapeutics is headquartered in Cambridge, United States.

What industry is Arsia Therapeutics in?

Arsia Therapeutics operates in Biotech, Healthcare.

Arsia Therapeutics

Acquired

Cambridge, United States · Founded 2013 · $1.1M raised

Biotech

Healthcare

Headquarters: Cambridge
Founded: 2013
Business Model: B2B

Total Funding: $1.1M
Last Round: $1.0M Series AJun 2015
Rounds: 2

About

Arsia Therapeutics was an early-stage biotechnology firm founded in 2013 by MIT professors Robert Langer and Alexander Klibanov, together with Polaris Partners, to improve the delivery of highly viscous protein therapeutics. Arsia's proprietary formulation platform enabled subcutaneous administration of high-dose biologics. Headquartered in Kendall Square, Cambridge, Massachusetts, the company was acquired by Eagle Pharmaceuticals in 2016 for up to $78 million.

Summary

Arsia Therapeutics is a Biotech company based in Cambridge, United States, founded in 2013. It has raised $1.1M in total across 2 rounds, most recently a $1.0M Series A round in Jun 2015. Investors include Polaris Partners and Eagle Pharmaceuticals.